In Brief: LaserSight
This article was originally published in The Gray Sheet
Executive Summary
LaserSight: Company will focus resources on its laser platform for refractive surgery after gaining approximately $13 mil. from the sale of two of their subsidiaries, MEC Health Care and LSI Acquisition, to Vision Twenty-One. The deal, announced Dec. 31, gives LaserSight $6.5 mil. paid in cash at closing and about $6.5 mil. paid in common stock of Vision Twenty-One. The company estimated after-tax gain of $1.5 mil. to $2 mil. from the transaction, which is subject to post-closing adjustments. MEC Health Care administers HMO and self-insured vision plans; LSI Acquisition is a practice management company that oversees the ophthalmic business known as the Northern New Jersey Eye Institute...
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.